Advertisement

Topics

Latest "Reddy Laboratories" News Stories

12:33 EDT 18th October 2018 | BioPortfolio

Here are the most relevant search results for "Reddy Laboratories" found in our extensive news archives from over 250 global news sources.

More Information about Reddy Laboratories on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Reddy Laboratories for you to read. Along with our medical data and news we also list Reddy Laboratories Clinical Trials, which are updated daily. BioPortfolio also has a large database of Reddy Laboratories Companies for you to search.

Showing "Reddy Laboratories" News Articles 1–25 of 2,100+

Extremely Relevant

Dr. Reddy’s Laboratories sells antibiotic manufacturing site in Bristol, Tennessee

Under the terms of the agreement, Dr. Reddy’s sold all the issued and outstanding membership interests in Dr. Reddy’s Laboratories Tennessee, LLC and certain related assets. Dr. Reddy’s The post Dr. Reddy’s Laboratories sells antibiotic manufacturing site in Bristol, Tennessee appeared first on Pharma Business review.


Dr. Reddy's Laboratories Regains Worldwide Rights To DFA-02

NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY), along with its subsidiaries, announced the termination of the license granted to Armis Biopharma, Inc. for its investigational antibacter...

Dr. Reddy's Laboratories Launches Hervycta In India

NewsDr. Reddy’s Laboratories has launched Hervycta, a biosimilar of Roche’s Herceptin, in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer, and metastatic gastric cancer).


Deals this week: Dr. Reddy’s Laboratories, Pluristem Therapeutics, Fortress Biotech

Dr. Reddy’s Laboratories has signed a distribution agreement with UCB to supply the latter’s epilepsy drug Briviact in India. As...Read More... The post Deals this week: Dr. Reddy’s Laboratories, Pluristem Therapeutics, Fortress Biotech appeared first on Pharmaceutical Technology.

FDA Approves First Generic Version Of Suboxone

NewsDr. Reddy's Laboratories announces final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. market.

Dr. Reddy's Laboratories announces its intent to appeal court decision in preliminary ...

Dr. Reddy’s Laboratories Ltd.INVESTOR RELATIONSSAUNAK SAVLA, +91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCALVIN PRINTER, +91-40-49002121calvinprinter@drreddys.com Read more...

Dr Reddy's Laboratories net jumps to Rs. 456 crore in Q1

Dr Reddy's Laboratories, a Rs. 14,200 crore plus fifth largest Indian phrma major, has posted growth in net profit during the first quarter ended June 2018 on account of launch of new product in US and emerging markets.

Dr. Reddy’s Laboratories defends its right to launch Buprenorphine and Naloxone Sublingual Film in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that following the launch of its generic Buprenorphine and Naloxone Sublingual Film in the U.S. Market, the U.S. District Court for the District … Continue reading → Cet article Dr. Reddy’s Laboratories defends its right to lau...

FDA approves Dr. Reddy's Aggrenox generic capsules

Dr. Reddy's Laboratories' Aspirin and Extended-Release Dipyridamole capsules was granted approval by the FDA.  -More- 

BRIEF—Dr Reddy’s files NDA for its migraine candidate

India’s Dr Reddy’s Laboratories has announced the filing of New Drug Application (NDA) for its migraine…

US FDA clears troubled API plants following two Form 483s, says Dr. Reddy’s

Dr. Reddyâs Laboratories has announced receipt of a US FDA establishment inspection report regarding two active pharmaceutical ingredient plants in Hyderabad, India.

Dr. Reddy's Laboratories Limited Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175

Dr. Reddy's Laboratories Limited Strategy, SWOT and Corporate Finance ReportSummaryDr. Reddy's Laboratories Limited Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key HighlightsDr. Re...

Relevant

Dr. Reddy’s Laboratories Announces FDA Final Approval and Launch of Buprenorphine and Naloxone Sublingual Film

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent …

Dr. Reddy’s launches Herceptin biosimilar in India

Dr. Reddyâs Laboratories has announced its biosimilar version of Rocheâs Herceptin, Hervycta (trastuzumab), is now available on the Indian market.

Dr. Reddy's granted Indian rights to epilepsy therapy

UCB has granted Dr. Reddy's Laboratories exclusive rights to market Briviact, or brivaracetam, in India.  -More- 

Dr. Reddy’s recalling 236,000 bottles of statins from US

The US FDA has announced that over 236,000 bottles of statins will be voluntarily recalled by Dr. Reddyâs Laboratories, after issues were found with impurities.

Dr. Reddy’s in Fresh Asset Sale

India’s Dr. Reddy's Laboratories has entered a definitive agreement to sell its API manufacturing business unit at Jeedimetla, Hyderabad, Pakistan, to Therapiva Private Ltd, an emerging generics pharmaceutical company headquartered in Abu Dhabi, United Arab Emirates.

Dr. Reddy's Launches Generic Version Of Nexium 24HR Capsules

NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter therapeutic equivalent generic ver...

US court issues a restraint order against Dr Reddy’s new drug

Indian pharmaceutical company Dr Reddy’s Laboratories has announced that the US District Court in New Jersey has issued a temporary restraining...Read More... The post US court issues a restraint order against Dr Reddy’s new drug appeared first on Pharmaceutical Technology.

Dr Reddy's Labs' sales and profit under pressure in Q4, dividend at 400%

Dr Reddy's Laboratories (DRL), a Rs. 14,200 crore plus pharma major, has suffered another setback during the fourth quarter ended March 2018 on account of stagnant sales, significant higher tax provisions, price erosion

Indivior seeks injunction to block Dr. Reddy’s generic launch in US

Indivior has requested a temporary restraining order against Dr. Reddyâs Laboratories to prevent further sales of its generic buprenorphine and naloxone sublingual film product in the US.

Dr. Reddy’s Files NDA for Migraine Treatment

Migraine sufferers could have a new treatment option. India-based Dr. Reddy’s Laboratories and its subsidiary Promius Pharma, LLC filed a NDA with the U.S. FDA for approval of migraine candidate DFN-02.

Dr. Reddy's Labs Launches Neostigmine Methylsulfate Injection, USP In U.S.

NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz or Ne...

Job Cuts Seen At Dr Reddy’s Amid Cost Recalibration

Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and...   

Dr. Reddy’s, Mylan Secure Approval for Suboxone Generic, Shares of Indivior Fall on the News

Shares of Dr. Reddy’s Laboratories Ltd. are surging this morning after the FDA approved its generic version of Suboxone (buprenorphine and naloxone) sublingual film for opioid addiction.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks